Kidney
Newsletter
Keeping you up to date with the latest exciting advances and discussions in nephrology
Clinical challenges in kidney disease management
ANCA-associated vasculitis (AAV) is a group of rare, severe autoimmune diseases affecting small-medium blood vessels throughout the body1–4
![](/themes/custom/kidney_newsletter/img/aav-desc-img.png)
granulomatosis with polyangiitis (previously called Wegener’s disease)
microscopic polyangiitis
eosinophilic granulomatosis with polyangiitis(previously called Churg–Strauss syndrome)
AAV may cause irreversible damage to vital organs, with the kidneys and lungs as major targets2–4
![](/themes/custom/kidney_newsletter/img/aav-add-desc-img1.png)
(GPA: 7–8%)
Severe inflammation of the sclera
![](/themes/custom/kidney_newsletter/img/aav-add-desc-img3.png)
(GPA & MPA: 60–80%)
Alveolar hemorrhage
![](/themes/custom/kidney_newsletter/img/aav-add-desc-img5.png)
(GPA: 25%; MPA: 35%)
Painful neuropathy
![](/themes/custom/kidney_newsletter/img/aav-add-desc-img2.png)
(GPA: 50–95%; MPA: 2–30%)
Nasal/sinus ulceration and destruction
![](/themes/custom/kidney_newsletter/img/aav-add-desc-img4.png)
(GPA: 50–95%; MPA: 2–30%)
Deafness
![](/themes/custom/kidney_newsletter/img/aav-add-desc-img6.png)
(GPA: 60–80%; MPA: 80%)
Renal impairment/failure
Renal involvement in AAV increases risk of ESRD and mortality6–10
At remission induction6
![](/themes/custom/kidney_newsletter/img/aav-risk-img3.png)
More patients need dialysis as disease progresses
![](/themes/custom/kidney_newsletter/img/aav-risk-img5.png)
Within 5 years of diagnosis:7,8
![](/themes/custom/kidney_newsletter/img/aav-risk-img4.png)
![](/themes/custom/kidney_newsletter/img/aav-risk-img1.png)
![](/themes/custom/kidney_newsletter/img/aav-risk-img2.png)
FOOTNOTES
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic auto-antibody; BVAS, Birmingham Vasculitis Activity Score; EGPA, eosinophilic granulomatosis with polyangiitis; ERA-EDTA, European Renal Association-European Dialysis and Transplant Association; ESRD, end-stage renal disease; EULAR, European Alliance Of Associations For Rheumatology;
GC, glucocorticoid; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis.
REFERENCES
- Al-Hussain T, et al. Adv Anat Pathol 2017;24:226–34;
- Yates M, et al. Ann Rheum Dis 2016;75:1583–94;
- Jennette JC, et al. Arthritis Rheum 2013;65:1–11;
- Wallace ZS, Miloslavsky EM. BMJ 2020;368:m421;
- Pagnoux C. Eur J Rheumatol 2016;3:122–33;
- Rutherford PA, Götte D. EMJ Nephrol 2020;8[Suppl 4]:2–16;
- Mohammed AJ, Segelmark M. J Rheumatol 2014;14:1366–73;
- Takala JH, et al. Scand J Rheumatol 2011;40:283–8;
- Hejil C, et al. RMD Open 2017;3:e000435–10;
- Mahr A, et al. Ann Rheum Dis 2013;72:1003–10;
- Hellmich B, et al. Ann Rheum Dis 2007;66:605–17;
- Stone JH, et al. N Engl J Med 2010;363:221–32;
- Specks U, et al. N Engl J Med 2013;369:417–27;
- Charles P, et al. Ann Int Med 2020;10.7326/M19-3827;
- Robson J, et al. Ann Rheum Dis 2015;74:177–84;
- Little MA, et al. Ann Rheum Dis 2010;69:1036−43;
- Robson J, et al. Rheumatol Int 2018;38:675–82;
- Jennette JC, Nachman PH. Clin J Am Soc Nephrol 2017;12:1680–91.